Sukumar Nagendran
President at TAYSHA GENE THERAPIES, INC.
Net worth: 114 161 $ as of 29/04/2024
Sukumar Nagendran active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SOLID BIOSCIENCES INC. | Director/Board Member | 11/09/2018 | - |
| Independent Dir/Board Member | 11/09/2018 | - | |
| TAYSHA GENE THERAPIES, INC. | Director/Board Member | 30/06/2020 | - |
| Chief Tech/Sci/R&D Officer | 15/12/2022 | - | |
| President | 15/12/2022 | - | |
| Independent Dir/Board Member | 30/06/2020 | 15/12/2022 | |
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Director/Board Member | 26/02/2019 | - |
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Director/Board Member | - | - |
Medocity, Inc.
 Medocity, Inc. Medical/Nursing ServicesHealth Services Medocity, Inc. develops a care platform that bridges the gap between the clinic and the patient?s home. It offers a patient-centric mobile solution that combines key aspects of disease-specific care into a platform that can be used on application and Web-based devices. The firm platform also tracks key symptoms and side effects in real time; displays reports and graphic summaries to understand the patient?s health status on a daily basis. The company is headquartered in Parsippany, NJ. | Director/Board Member | - | - |
Career history of Sukumar Nagendran
Former positions of Sukumar Nagendran
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOVANT, INC. | Director/Board Member | 28/02/2019 | 30/11/2019 |
| AVEXIS INC | Chief Tech/Sci/R&D Officer | 31/08/2015 | 30/06/2018 |
RestorGenex Corp.
 RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | Director of Finance/CFO | 31/12/2013 | 31/12/2015 |
| QUEST DIAGNOSTICS INCORPORATED | Corporate Officer/Principal | 28/02/2013 | 31/08/2015 |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ ░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░ ░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Sukumar Nagendran
| Rutgers State University of New Jersey | Undergraduate Degree |
| Rutgers Robert Wood Johnson Medical School | Doctorate Degree |
Statistics
International
| United States | 14 |
| France | 2 |
| Japan | 2 |
Operational
| Director/Board Member | 6 |
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 3 |
Sectoral
| Health Technology | 9 |
| Health Services | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| QUEST DIAGNOSTICS INCORPORATED | Health Services |
| SOLID BIOSCIENCES INC. | Health Technology |
| DAIICHI SANKYO CO., LTD. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Private companies | 9 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Health Technology |
Health Sciences Acquisitions Corp.
 Health Sciences Acquisitions Corp. Financial ConglomeratesFinance Health Sciences Acquisitions Corp. operates as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It pursues prospective targets that are focused on healthcare innovation domiciled in North America or Europe that are developing assets in the biopharma and medical technology sectors. The company was founded on December 06, 2018 and is headquartered in New York, NY. | Finance |
The Robert Wood Johnson Foundation
 The Robert Wood Johnson Foundation Investment Trusts/Mutual FundsMiscellaneous The Robert Wood Johnson Foundation (RWJF) is an independent philanthropic organization headquartered in Princeton, New Jersey. The firm was founded in 1972 and is dedicated solely to health. RWJF funds a wide array of programs which are working to help build a national Culture of Health. | Miscellaneous |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Health Technology |
Jaguar Gene Therapy LLC
 Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Health Services |
RestorGenex Corp.
RestorGenex Corp. Pharmaceuticals: MajorHealth Technology RestorGenex Corp. operates as a specialty biopharmaceutical company, which focuses on developing products for dermatology, ophthalmology, and oncology. It products includes novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically glioblastoma multiforme. The company current pipeline also includes a soft anti-androgen compound for the treatment of acne vulgaris. RestorGenex was founded on March 14, 2008 and is headquartered in Buffalo Grove, IL. | Health Technology |
Medocity, Inc.
Medocity, Inc. Medical/Nursing ServicesHealth Services Medocity, Inc. develops a care platform that bridges the gap between the clinic and the patient?s home. It offers a patient-centric mobile solution that combines key aspects of disease-specific care into a platform that can be used on application and Web-based devices. The firm platform also tracks key symptoms and side effects in real time; displays reports and graphic summaries to understand the patient?s health status on a daily basis. The company is headquartered in Parsippany, NJ. | Health Services |
- Stock Market
- Insiders
- Sukumar Nagendran
- Experience
